Heron Therapeutics (HRTX) Work In Process (2016 - 2026)

Heron Therapeutics has reported Work In Process for 11 years, with the latest figure at $21.6 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process fell 25.32% year-over-year to $21.6 million; the trailing twelve-month figure through Mar 2026 stood at $21.6 million (down 25.32% YoY), and the FY2025 full-year result was $26.6 million, down 2.12% from the prior year.
• Work In Process for Q1 2026 stood at $21.6 million, down from $26.6 million in the prior quarter.
• The five-year high for Work In Process was $29.0 million in Q1 2025, with the low at $9.0 million in Q2 2023.
• Historically, Work In Process has averaged $19.5 million across 5 years, with a median of $18.4 million in 2024.
• Annual changes were most pronounced in 2023 — Work In Process tumbled 55.18% — and 2024, when it soared 86.87%.
• Heron Therapeutics' Work In Process stood at $20.7 million in 2022, then decreased by 29.79% to $14.6 million in 2023, then soared by 86.87% to $27.2 million in 2024, then slipped by 2.12% to $26.6 million in 2025, then decreased by 18.75% to $21.6 million in 2026.
• The last three Work In Process figures came in at $21.6 million (Q1 2026), $26.6 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.